Date: 2015-09-28
Type of information: Collaboration agreement
Compound: MRI biomarkers MSmetrix
Company: icometrix (Belgium) Novartis (Switzerland)
Therapeutic area: Neurodegenerative diseases - Diagnostic
Type agreement: collaboration
Action mechanism: biomarker. MSmetrix is a CE-labeled brain atrophy and lesion measurement tool for multiple sclerosis (MS). MSmetrix uses standard, clinical MRI images and is approved for clinical practice in Europe, Canada and many other
countries worldwide.
Disease: multiple sclerosis
Details: * On September 28, 2015, icometrix, a leader in MRI biomarkers for multiple sclerosis patients, announced that they have signed a collaboration agreement with Novartis Pharma to provide MSmetrix to individual MS patients worldwide. icometrix developed MSmetrix, a clinical “brain” report that automatically detects existing, new or enlarging brain lesions, calculates lesion volume and measures the whole brain and grey matter volume and atrophy.
Since the approval for clinical use in Europe, Canada, Brazil and Australia in April 2015, more than 100 hospitals are using MSmetrix reports to better understand the disease activity of individual patients. The MSmetrix software was specifically designed for patients with MS, resulting in a very small measurement error, which is essential for detecting the small yearly brain MRI changes.
Financial terms:
Latest news:
